Search

Digital oral presentations: DOP Session 3 - Improving care of IBD (2020)

DOP19 Real-world healthcare resource utilisation among patients with inflammatory bowel disease administered vedolizumab for 6 months

DOP20 Can lifestyle and psychosocial factors predict flares of IBD; an exploratory study using telemedicine

DOP21 Time to first treatment with biologic agents for ulcerative colitis and Crohn’s disease across four Nordic countries: Results from the TRINordic study

DOP22 Certification of integral care IBD Units: Evaluation of a certification program (CUE)

DOP23 Endoscopic evaluation at 1 month after ileocolic resection for Crohn’s disease predicts postoperative recurrence and is safe

DOP24 Patient-reported health-related quality-of-life outcomes with vedolizumab vs. adalimumab treatment of ulcerative colitis: Results of the VARSITY trial

DOP25 Medication use and comorbidities among elderly when compared with younger patients with inflammatory bowel disease in the TARGET-IBD cohort

DOP26 Real-life dosing patterns and concomitant drug use among ustekinumab-treated patients with Crohn’s disease

DOP27 Transanal minimally invasive surgery (TAMIS): A novel approach for treatment of pouch failure